Home › Funds › Patient Square Capital LP › BNTX
Patient Square Capital LP position in BNTX
BIONTECH SE · Health Care
Patient Square Capital LP reported holding 105,421 shares of BNTX (BIONTECH SE) in its Q3 2026 13F filing — a position valued at US$10.4M, representing 1.65% of its reported portfolio and ranking #16 among its reported holdings. Patient Square Capital LP has disclosed BNTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Square Capital LP's BNTX position evolved
Patient Square Capital LP first disclosed a stake in BNTX in Q2 2026 at 134,429 shares (US$12.5M). Across 2 filings, Patient Square Capital LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 105,421 shares valued at US$10.4M — a reduction of -29,008 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 134.43K | $12.51M | New |
| Q3 2026 | 105.42K | $10.36M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BNTX and 13F data
BNTX (BIONTECH SE) is a Health Care company. 29 other funds we track also report a position in BNTX — the largest reported positions include Logos Global Management LP (US$94.4M), Davern Capital Partners, LP (US$67.1M), GSK plc (US$65.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BNTX
- Logos Global Management LP 1.01M sh · $94.45M · Q2 2026
- Davern Capital Partners, LP 682.15K sh · $67.06M · Q3 2026
- GSK plc 668.53K sh · $65.72M · Q3 2026
- Long Focus Capital Management, LLC 624.00K sh · $58.06M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 470.00K sh · $43.73M · Q2 2026
- LBP AM SA 329.27K sh · $32.37M · Q3 2026
More on Patient Square Capital LP
FAQ
How long has Patient Square Capital LP held BNTX?
Patient Square Capital LP has disclosed BNTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Patient Square Capital LP's current position in BNTX?
As of Q3 2026, Patient Square Capital LP holds 105.42K shares of BNTX (BIONTECH SE), valued at $10.36M, representing 1.65% of its reported portfolio and ranking #16.
Has Patient Square Capital LP been buying or selling BNTX?
In the latest 13F filing (Q3 2026), Patient Square Capital LP reduced its position in BNTX.
Which other funds hold BNTX?
Other major institutional holders of BNTX include Logos Global Management LP, Davern Capital Partners, LP, GSK plc, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.